UBI results Diversified revenue mix: Two commercial products on...

UBI results

Diversified revenue mix: Two commercial products on market
• Strong momentum in revenue growth:
 Total revenue growth up 76% on pcp to $16.8M
 Quarterly Service Fees up 99% on pcp to $12.8M
 Coagulation strip sales to Siemens up over 500% on pcp to $1.3M
• Improved financial metrics:
 Net loss reduced to $6.6M (down from $9.3M on pcp)
 Operating cash flow positive of $1.8M (vs negative $5.4M in pcp)
• Efficient R&D investment:
 Total development expense of $19.8M (up 15% on pcp)
 Net development expense of $10.5M (up 46% on pcp)
 Partner contributions (incl. milestones) of $2.0M (up 12% on pcp